Congress Materials – European Respiratory Society (ERS 2025)
2025 European Respiratory Society | Sep 27 - Oct 1 | Amsterdam, Netherlands
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Dose rationale for UNISUS, an ongoing, event-driven, phase III superiority study evaluating macitentan 75mg vs 10mg in pulmonary arterial hypertension (PAH)
Dénes Csonka, Juan Jose Perez Ruixo
Real-world clinical outcomes according to individualised selexipag dose in pulmonary arterial hypertension (PAH)
Lange TJ, Escribano-Subias P, Borissoff JI, Fernandes CC, Fontana M, Venkatesh A, Söderberg S, Gaine S
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
